Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy
Approximately 4% of cancer patients have non-valvular atrial fibrillation (NVAF) and require anticoagulation for...
ARCHIVE
Cancers as coagulant mosaics
Cancers are potent inducers of abnormal blood clotting, which usually heralds a more aggressive course of the disease...
ICTHIC at ISTH 2019 – come find us
This year ICTHIC Magazine is travelling all the way to Melbourne to attend the 26th ISTH. Come and find us...
Cancer associated thrombosis at ISTH: what not to miss
At ISTH 2019, this year held in Melbourne, thousands of the world’s leading experts on thrombosis, hemostasis and...
Arterial Thromboembolism in Occult Cancer
In 1865, Armand Trousseau famously described unexplained thrombotic events as a first manifestation of occult...
Contemporary breast cancer treatment-associated venous thromboembolism
Breast cancer patients have a three-to four fold increased risk of venous thromboembolism (VTE) when compared to women...
The XXVII Congress of the International Society on Thrombosis and Haemostasis
Taking place in Melbourne, Australia, July 6-10, 2019, the ISTH 2019 celebrates its 27th Edition and features the...
Mouse models of cancer-associated thrombosis
Cancer patients have 4-7 fold increased risk of venous thromboembolism (VTE) compared with a general population ....
Welcome LEO Pharma
Founded in 1908, LEO Pharma is a foundation-owned company that has devoted decades of research and development to...
DOACs in the treatment of cancer-associated thrombosis
Since the publication of the SELECT-D trial1 and the Hokusai-VTE Cancer study2, there has been a shift in the...